Message Font: Serif | Sans-Serif
No. of Recommendations: 4
Good news is that it will be at least 2 years until they go back for more financing (absent something egregious that might happen). $400 million in cash left at end of 2013.

They now have 2 drugs, and 3 indications in Phase III. Castrate of course, HCC and RCC, they have the partnered drug, and MTC indication approved (which probably, financially, had been better to have not been pursued as the return is going to be very small).

Share price taking a hit however, sell on the news, although there was no rise on the rumor to go along with it. Just more watching the paint dry I think, except the paint, like the continents, is actually moving and doing so dramatically, just mostly imperceivable if you don't know where to look.

Something like that....

But the Cabo franchise is proceeding forward now with 1 approved indication and 2 phase III alternative indications, and 1 partnered drug with a yet totally different indication in Phase III as well.

The share price is low, but the market cap is still nothing to sneeze at, so it is not as if the market does not understand some of this, but it is frustrating when we see what a DNDN or a VRTX can run to once their drug is finally approved.

DNDN staggered like this until actual approval, and VRTX went up and down and up and down, even when it was obvious and apparent that telaprevir would be approved, would be the best drug, and would have a substantial market.

Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.